SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Faruqi & Faruqi, LLP, a prominent national securities law firm, is investigating potential legal claims on behalf of investors in Skye Biosciences, Inc. (“Skye”) (NYSE: SKYE) related to possible violations of federal securities laws. The firm’s Securities Litigation Partner, James (Josh) Wilson, is encouraging investors who purchased or acquired Skye securities between November 4, 2024, and October 3, 2025, and suffered losses to contact the firm to discuss their options. The firm also reminded investors of the upcoming January 16, 2026 deadline to seek appointment as lead plaintiff in a federal securities class action that has been filed against Skye. Faruqi & Faruqi alleges that Skye and its executives made false or misleading statements and failed to disclose material information, particularly concerning the performance and prospects of the drug nimacimab, leading to a significant drop in the company’s stock price following disappointing clinical data. Investors, whistleblowers, former employees, shareholders, and others with relevant information are encouraged to reach out. For more details or to participate, contacts and additional information are provided through the firm’s channels. #SkyeBioscience #ClassAction #FaruqiAndFaruqi #InvestorRights #SlimScan #GrowthStocks #CANSLIM